312 related articles for article (PubMed ID: 17390024)
1. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Richard CL; Blay J
Int J Oncol; 2007 May; 30(5):1215-22. PubMed ID: 17390024
[TBL] [Abstract][Full Text] [Related]
2. 15-Deoxy-delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways.
Richard CL; Lowthers EL; Blay J
Exp Cell Res; 2007 Oct; 313(16):3446-58. PubMed ID: 17707368
[TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
4. Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression.
Rovito D; Gionfriddo G; Barone I; Giordano C; Grande F; De Amicis F; Lanzino M; Catalano S; Andò S; Bonofiglio D
Oncotarget; 2016 Oct; 7(40):65109-65124. PubMed ID: 27556298
[TBL] [Abstract][Full Text] [Related]
5. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
6. Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion.
Yang DR; Lin SJ; Ding XF; Miyamoto H; Messing E; Li LQ; Wang N; Chang C
Urology; 2013 May; 81(5):1109.e1-6. PubMed ID: 23522297
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma.
Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH
Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
[TBL] [Abstract][Full Text] [Related]
9. MCC-555-induced NAG-1 expression is mediated in part by KLF4.
Cekanova M; Lee SH; McEntee MF; Baek SJ
Eur J Pharmacol; 2010 Jul; 637(1-3):30-7. PubMed ID: 20385121
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC
Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Akinyeke TO; Stewart LV
Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone.
Yaacob NS; Darus HM; Norazmi MN
Exp Toxicol Pathol; 2008 Sep; 60(6):505-12. PubMed ID: 18579355
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.
Yang CC; Ku CY; Wei S; Shiau CW; Chen CS; Pinzone JJ; Ringel MD; Chen CS
Mol Pharmacol; 2006 May; 69(5):1564-70. PubMed ID: 16452400
[TBL] [Abstract][Full Text] [Related]
15. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model.
Shimazaki N; Togashi N; Hanai M; Isoyama T; Wada K; Fujita T; Fujiwara K; Kurakata S
Eur J Cancer; 2008 Aug; 44(12):1734-43. PubMed ID: 18511262
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cigarette smoke-induced toll-like receptor 4 expression by peroxisome proliferator-activated receptor-gamma agonists in bronchial epithelial cells.
Yin Y; Hou G; Li ER; Wang QY; Kang J
Respirology; 2013 Nov; 18 Suppl 3():30-9. PubMed ID: 24188201
[TBL] [Abstract][Full Text] [Related]
18. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
Huang JW; Shiau CW; Yang YT; Kulp SK; Chen KF; Brueggemeier RW; Shapiro CL; Chen CS
Mol Pharmacol; 2005 Apr; 67(4):1342-8. PubMed ID: 15653552
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Pavlov TS; Levchenko V; Karpushev AV; Vandewalle A; Staruschenko A
Mol Pharmacol; 2009 Dec; 76(6):1333-40. PubMed ID: 19752200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
